Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company's primary focus is on therapies for life-threatening infectious diseases, particularly HIV/AIDS and hepatitis B and C. Gilead's portfolio includes the hepatitis C drug Sovaldi, which emerged from its acquisition of Pharmasset, and is part of established combination treatment regimens. Additionally, Gilead is expanding its presence in oncology through strategic acquisitions, including CAR-T cell therapies such as Yescarta and Tecartus, as well as breast and bladder cancer treatments like Trodelvy. By concentrating on these critical areas, Gilead aims to enhance patient care and outcomes for those with serious health conditions.

Matthew Bryant

Head of Technology and Innovation, Executive Director, Global Development / Clinical Operations

Jane Stafford

Director

92 past transactions

Assembly Biosciences

Post in 2024
Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative therapies for hepatitis B virus (HBV) infection and microbiome-related disorders. The company's HBV program is advancing multiple oral therapeutic candidates aimed at improving cure rates for chronic HBV by targeting various stages of the viral lifecycle through core protein inhibitors. Concurrently, its microbiome program employs a comprehensive platform that includes strain identification, isolation, and a patented delivery system, GEMICEL, for targeted oral delivery of therapeutics to the lower gastrointestinal tract. This program is developing novel oral biotherapeutics to address conditions such as Crohn's disease and C. difficile infections. Assembly has established collaboration agreements with Allergan Pharmaceuticals and Door Pharmaceuticals to further develop its microbiome and HBV programs, respectively. Since its inception in 2005, the company has evolved from its previous identity as Ventrus Biosciences, Inc., reflecting its commitment to advancing impactful treatments in the biotechnology sector.

Children's Inn At NIH

Grant in 2024
The Children’s Inn at NIH enhances the opportunities for groundbreaking medical discoveries by providing a free “place like home” that reduces the burdens of illness through a supportive environment that includes therapeutic, educational, and recreational programming for children.

Assembly Biosciences

Post in 2024
Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative therapies for hepatitis B virus (HBV) infection and microbiome-related disorders. The company's HBV program is advancing multiple oral therapeutic candidates aimed at improving cure rates for chronic HBV by targeting various stages of the viral lifecycle through core protein inhibitors. Concurrently, its microbiome program employs a comprehensive platform that includes strain identification, isolation, and a patented delivery system, GEMICEL, for targeted oral delivery of therapeutics to the lower gastrointestinal tract. This program is developing novel oral biotherapeutics to address conditions such as Crohn's disease and C. difficile infections. Assembly has established collaboration agreements with Allergan Pharmaceuticals and Door Pharmaceuticals to further develop its microbiome and HBV programs, respectively. Since its inception in 2005, the company has evolved from its previous identity as Ventrus Biosciences, Inc., reflecting its commitment to advancing impactful treatments in the biotechnology sector.

Leap Therapeutics

Post in 2024
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of targeted and immuno-oncology therapies for cancer treatment. Founded in 2011 and previously known as HealthCare Pharmaceuticals, the company focuses on identifying and developing molecules that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1) and is currently undergoing clinical trials for various cancers, including esophagogastric and gynecologic cancers. Additionally, Leap Therapeutics is advancing its second program, FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative treatments for cancer.

SisterLove

Grant in 2024
SisterLove is a foundation located in Atlanta, Georgia, founded in 1989. Its mission is to address and eradicate the negative effects of HIV/AIDS and other reproductive health challenges that disproportionately affect women and their families. The organization focuses on education, prevention, support, research, and advocacy for health rights and justice, both in the United States and globally. SisterLove is dedicated to empowering women by providing essential resources and promoting awareness about reproductive health issues.

A New Way of Life Reentry Project

Grant in 2024
A New Way of Life Reentry Project is a non profit organization that provides housing and reentry support to formerly incarcerated women and their children. A New Way of Life operates a total of four sober living homes, serving 40-50 women and children per year, and offers a wide range of support services to help facilitate a successful transition back to community life. Since its founding in 1998, A New Way of Life has helped transform the lives of over 220 women.

Transinclusive Group

Grant in 2024
Transinclusive Group is a Transgender-Led TLGBQ+ tax exempt, non-profit organization. As an advocacy driven organization, its goal is to cultivate advocates to take action to influence social, political, and economic systems to bring about change for all TLGBQ+ individuals.

National Association of Black Social Workers

Grant in 2024
National Association of Black Social Workers is a non-profit that aims to enhance life and empower people of African ancestry.

Ribbon

Grant in 2024
Ribbon is a Center of Excellence that specializes in skill-building training and technical assistance, long-term organizational development, and leadership development.

SLK Health Services Corporation

Grant in 2024
SLK is a community- based health care organization. It promotes the prevention and eradication of illnesses and infections among vulnerable communities, especially high-risk negatives and the LGBTQ community.

Triumphant 2Gether

Grant in 2024
Triumphant 2Gether is a tax-exempt, nonprofit organization. It empowers women and girls impacted by violence through policy advocacy and social service projects.

WeCareTn

Grant in 2024
WeCareTn is a non-profit organization build to support transwomen. It supports Transwomen of color through education and empowerment with the goal that they have the same equity and quality of life as envisioned.

Unspoken Treasure Society

Grant in 2024
Unspoken Treasure Society is a non-profit organization committed to meeting the needs of our TRANS community.

Baltimore Safe Haven

Grant in 2024
Baltimore Safe Haven provides opportunities for TLGBQ people. They providing housing services and food distributing services for TLGBQ community.

Howard University

Grant in 2024
Howard University, located in Washington, D.C., is an esteemed institution established in 1867 that focuses on providing educational opportunities, particularly for African-American students. The university offers a wide range of academic programs at the undergraduate, graduate, and doctoral levels, including fields such as law, medicine, and pharmaceutical studies. With a commitment to fostering high academic achievement and potential, Howard University aims to enhance the educational landscape while reflecting the political and cultural dynamics of its environment.

California Black Women’s Health Project

Grant in 2024
The California Black Women's Health Project is the only statewide, non-profit organization that is solely committed to ​improving the health of California's 1.2 million Black women and girls through advocacy, education, outreach and policy.

AIDS United

Grant in 2024
AIDS United is ending the U.S. HIV epidemic through grantmaking, capacity-building, technical assistance, and advocacy.

Dancing Grounds

Grant in 2024
Dancing Grounds is a nonprofit organization and dance studio with adult fitness and dance classes.

San Francisco Community Health Center

Grant in 2024
San Francisco Community Health Center is a health organization that focuses on advancing health, wellness, and equality in the community.

Power Safe Place Resource Center of Virginia

Grant in 2024
PSPRCVA offers a safe haven for Virginia's People of Color - LGBTQ+ community and other marginalised people.

Black Women’s Learning Institute

Grant in 2024
BWLI is a national institute at NDRI-USA Inc., a not-for-profit research and development organization which provides high-impact actionable solutions to pressing public health problems. Its mission is to improve health and wellness for Black women across the lifespan through innovative resources, programmatic support, and culturally-relevant public health education.

WACO Theater Center

Grant in 2024
WACO (Where Art Can Occur) Theater Center is a cultural institution that promotes modern African Diaspora performing and visual arts.

CymaBay Therapeutics

Acquisition in 2024
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

Arcus Biosciences

Post in 2024
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Hookipa Pharma

Post in 2023
Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Assembly Biosciences

Post in 2023
Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative therapies for hepatitis B virus (HBV) infection and microbiome-related disorders. The company's HBV program is advancing multiple oral therapeutic candidates aimed at improving cure rates for chronic HBV by targeting various stages of the viral lifecycle through core protein inhibitors. Concurrently, its microbiome program employs a comprehensive platform that includes strain identification, isolation, and a patented delivery system, GEMICEL, for targeted oral delivery of therapeutics to the lower gastrointestinal tract. This program is developing novel oral biotherapeutics to address conditions such as Crohn's disease and C. difficile infections. Assembly has established collaboration agreements with Allergan Pharmaceuticals and Door Pharmaceuticals to further develop its microbiome and HBV programs, respectively. Since its inception in 2005, the company has evolved from its previous identity as Ventrus Biosciences, Inc., reflecting its commitment to advancing impactful treatments in the biotechnology sector.

Tentarix Biotherapeutics

Series B in 2023
Tentarix Biotherapeutics is focused on developing innovative protein therapeutics that address significant challenges in the treatment of cancer, autoimmune diseases, and other medical conditions. The company utilizes a protein engineering platform that employs synthetic biology to create multispecific binding molecules with unique combined bioactivities. By leveraging fully human antibody variable domains, Tentarix aims to enhance specificity and therapeutic activity, offering clinicians new approaches to treatment that were previously unattainable.

Tentarix Biotherapeutics

Corporate Round in 2023
Tentarix Biotherapeutics is focused on developing innovative protein therapeutics that address significant challenges in the treatment of cancer, autoimmune diseases, and other medical conditions. The company utilizes a protein engineering platform that employs synthetic biology to create multispecific binding molecules with unique combined bioactivities. By leveraging fully human antibody variable domains, Tentarix aims to enhance specificity and therapeutic activity, offering clinicians new approaches to treatment that were previously unattainable.

Kyverna Therapeutics

Series B in 2023
Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

CDA Foundation

Grant in 2023
CDA Foundation is a non-profit organization that specializes in the study of complex and poorly-understood diseases.

XinThera

Acquisition in 2023
XinThera is a drug discovery company dedicated to developing precision medicines aimed at treating cancer and immunologic diseases. By utilizing advanced computational chemistry technologies, XinThera designs small molecule therapies that target well-validated and previously challenging targets in oncology and immunology. The company's focus on these promising targets enhances the potential for effective drug therapies, ultimately benefiting patients who face difficult-to-treat conditions.

Compassionate Atlanta

Grant in 2023
Compassionate Atlanta is a non-profit organization that offer community building, education, and town planning services in Atlanta.

Alliance of AIDS Services

Grant in 2023
Alliance of AIDS Services provides health care services. They provide resources and charitable services for AIDS patients. They improve the health of communities impacted by HIV/AIDS through compassionate and non-judgmental prevention, support services, and connection to care.

Pierce County AIDS Foundation

Grant in 2023
PCAF provides direct care services to HIV/AIDS patients as well as extensive outreach, education, and prevention programming.

Power Safe Place Resource Center of Virginia

Grant in 2023
PSPRCVA offers a safe haven for Virginia's People of Color - LGBTQ+ community and other marginalised people.

Helping Everyone Receive Ongoing and Effective Support

Grant in 2023
HEROES supports, educates, and uplifts our community through adult wellness, youth education, and community service.

My Brother's Keeper

Grant in 2023
MBK's objective is to improve the health and well-being of minority and marginalized people across the United States by providing leadership and engagement with the public and community healthcare providers. The HIV prevention services provided by MBK centered on developing and delivering a diverse set of educational and training programs in public health, social policy, action research, information technology, advocacy, coalition development, and capacity building. MBK built its dedication to HIV prevention among racial and ethnic minority communities through its significant expertise, as seen by its service to over 15,000 clients nationwide.

Central Illinois Friends

Grant in 2023
Central Illinois Friends provides compassionate and personalized care to people living with HIV and vulnerable community members who require comprehensive clinical and supportive services.

Empowering Transgender Services

Grant in 2023
Transgender Services Empowerment offers dependable services with the goal of empowering the underserved transgender and LGBT communities.

Yale Cancer Center

Venture Round in 2023
Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Nueva vida

Grant in 2023
Nueva vida goal is to educate, encourage, and empower Latinas whose lives are impacted by cancer. Nueva vida also works to promote timely access to cutting-edge cancer treatment.

Young Survival Coalition

Grant in 2023
Young Survival Coalition is engaged in the critical issues unique to young women and breast cancer. They work with survivors, caregivers, medical, research, advocacy, and legislative communities to increase the life expectancy for women diagnosed with breast cancer. They also produce free educational resources, such as the breast cancer navigator series, which are comprehensive guidebooks that address every phase of treatment and survivorship.

MiroBio

Acquisition in 2022
MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

AlloVir

Post in 2022
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Exavir Therapeutics

Seed Round in 2022
Exavir Therapeutics is a preclinical stage biotechnology company focused on developing innovative therapies to eliminate HIV and other viral infections. The company specializes in ultra-long-acting nano-medicines that utilize proprietary nanoformulations to achieve sustained release of active pharmaceutical ingredients. This approach not only targets chronic viral infections but also addresses central nervous system disorders, aiming to provide patients with more convenient and effective treatment options. By adopting a broad modality-agnostic strategy, Exavir Therapeutics seeks to advance the field of antiviral therapeutics and improve patient outcomes.

Curebase

Series B in 2022
Curebase is a company that develops software aimed at transforming the management of clinical trials. Founded in 2017 and based in San Francisco, California, its platform facilitates faster and more cost-effective trial execution by streamlining participant eligibility, enrollment, education, and consent processes. The software automates many manual steps and allows drug companies to efficiently distribute their trials to clinics. Additionally, it provides sponsors with access to real-time data, enabling them to monitor trial progress and manage information effectively. Curebase's services cater to various sectors, including medical devices, biotechnology, and digital health startups, enhancing the overall efficiency of clinical research.

Pardes Biosciences

Post in 2021
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections. It utilizes modern reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is an oral antiviral designed to treat and prevent infections from SARS-CoV-2, the virus responsible for COVID-19. By reimagining the patient journey, Pardes aims to provide accessible and convenient treatment options for both adult and pediatric patients, ultimately striving to improve health outcomes and respond effectively to global health crises.

Destination Tomorrow

Grant in 2021
Destination Tomorrow is the Black-led Transgender & Gender Non-Conforming (TGNC) grant-making agency. The Destination Tomorrow offers services that take LGBTQ/TGNC individuals off the path of requiring emergency care with a focus on economic, social and mental empowerment on a holistic level.

Gritstone bio

Post in 2021
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Tango Therapeutics

Post in 2021
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.

Lyndra Therapeutics

Series C in 2021
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Barinthus Biotherapeutics

Series B in 2021
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company utilizes proprietary modified simian adenoviral vectors, specifically ChAdOx1 and ChAdOx2, along with the Modified Vaccinia Ankara (MVA) boost vector, both of which are designed to be safe and non-replicative in humans. This combination approach has demonstrated the ability to generate significantly higher levels of CD8+ T cells compared to other methodologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs targeting solid tumors, viral infections, and prophylactic viral vaccines. In collaboration with the University of Oxford, the company co-invented a COVID-19 vaccine that has received approval for use in various regions worldwide.

Arcus Biosciences

Post in 2021
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

MYR Group

Acquisition in 2020
MYR Group Inc is a U.S.-based holding company that specializes in electrical construction services, primarily through its various subsidiaries. The company operates in two main segments: transmission and distribution, and commercial and industrial. In the transmission and distribution segment, MYR Group provides a range of services that include the design, engineering, procurement, construction, and maintenance of transmission and distribution networks and substation facilities. The commercial and industrial segment focuses on the design, installation, maintenance, and repair of wiring systems, as well as traffic networks and bridges. With a widespread network of local offices across North America, MYR Group is well-equipped to serve the electrical infrastructure market and has established itself as a leader in the industry. The company boasts one of the largest fleets of specialized transmission and distribution equipment in the region, supported by a skilled workforce and an experienced management team.

Immunomedics

Acquisition in 2020
Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that focuses on developing monoclonal antibody-based therapies for cancer treatment. The company's lead product, sacituzumab govitecan, is an antibody-drug conjugate targeting metastatic triple-negative breast cancer, where it is positioned as a third-line treatment in the United States. Additionally, Immunomedics is advancing several other candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company also explores collaborative clinical efforts with major pharmaceutical partners to enhance the development and application of its products. Founded in 1982, Immunomedics aims to deliver innovative treatments to patients with serious diseases, leveraging its capabilities to drive scientific advancements and operational effectiveness. As of late 2020, it operates as a subsidiary of Gilead Sciences, Inc.

Tango Therapeutics

Venture Round in 2020
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.

Tizona Therapeutics

Corporate Round in 2020
Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.

Glympse Bio

Series B in 2020
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Goldfinch Biopharma

Series B in 2020
Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Pionyr Immunotherapeutics

Corporate Round in 2020
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, that focuses on developing innovative cancer immunotherapies. Founded in 2015, the company aims to enhance the body's antitumor immunity by targeting the tumor microenvironment. Utilizing advanced target discovery and antibody generation technologies, Pionyr has created a unique approach called Myeloid Tuning™, which modifies the cellular infiltrate within tumors to improve the immune system's response against cancer. This strategy is intended to be particularly effective when used in conjunction with checkpoint inhibitors, offering new avenues for cancer treatment.

Arcus Biosciences

Post in 2020
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Forty Seven

Acquisition in 2020
Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.

Vineti

Series C in 2020
Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

National AIDS Memorial

Grant in 2019
The National AIDS Memorial relies solely on funding from longtime personal donors and corporate partners to support its mission as a dedicated space in the national landscape where millions of Americans touched directly or indirectly by AIDS can gather to heal, hope, and remember. The National AIDS Memorial, known as “the Grove”, was created more than twenty-eight years ago in San Francisco’s Golden Gate Park at the height of the HIV/AIDS epidemic as a place where those impacted by AIDS could both grieve and begin the process of healing. In 1996, legislation sponsored by U.S. Representative Nancy Pelosi was signed into law by President Clinton that elevated “the Grove” as this nation's sole federally-designated National AIDS Memorial. More than 50,000 individuals from around the world have contributed 225,000 volunteer hours to support the National AIDS Memorial and its mission.

Tmunity

Series B in 2019
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.

Galapagos

Post in 2019
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

AlloVir

Series B in 2019
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Goldfinch Biopharma

Corporate Round in 2019
Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Lyndra Therapeutics

Series B in 2019
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Glympse Bio

Series A in 2018
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Precision BioSciences

Series B in 2018
Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Tmunity

Series A in 2018
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.

Allogene Therapeutics

Series A in 2018
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf, genetically engineered allogeneic T cell therapies for cancer treatment. The company's pipeline includes UCART19, in development for relapsed/refractory acute lymphoblastic leukemia, and several preclinical allogeneic CAR T therapies targeting various cancers. Allogene's approach uses gene editing and advanced manufacturing technologies to create a scalable, broader patient eligibility option compared to autologous therapies. Revenue is primarily generated through collaborations and licensing agreements.

Tmunity

Series A in 2018
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.

Cell Design Labs

Acquisition in 2017
Cell Design Labs, Inc. is a biotherapeutics company based in San Francisco, California, focused on developing innovative cell-based therapies for cancer and other serious diseases. Established in 2015, the company aims to harness the immune system's capabilities to create advanced treatments that offer improved power, precision, safety, and durability. Cell Design Labs specializes in disruptive T cell receptor therapies, which modify the body's immune cells to specifically recognize and eliminate malignant cells. This approach enables researchers to efficiently develop effective cell-based therapies that address some of the most challenging medical conditions. The company operates as a subsidiary of Gilead Sciences, Inc.

Kite Pharma

Acquisition in 2017
Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.

Nimbus Therapeutics

Acquisition in 2016
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

EpiTherapeutics

Acquisition in 2015
EpiTherapeutics is dedicated to developing innovative cancer therapies through the exploration of epigenetics, a field advanced by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen. The company focuses on small-molecule therapies, specifically targeting enzymes that regulate transcription in cancerous cells. EpiTherapeutics has established a library of selective small molecule inhibitors aimed at epigenetic regulation, particularly histone demethylases. Its lead pre-clinical compounds are currently being investigated for their potential effectiveness in treating various forms of cancer.

Phenex Pharmaceuticals

Acquisition in 2015
Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002 and headquartered in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, focusing on nuclear receptors to address various disease areas, including liver diseases, intestinal diseases, and cancer. Current research includes developing RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. Phenex is dedicated to not only creating therapeutics for established targets but also identifying novel molecular mechanisms, which has led to the development of proprietary therapeutic small molecules. The company operates within the Biotech Cluster Rhine-Neckar, leveraging its expertise in biology and chemistry to advance innovative treatment options.

YM BioSciences

Acquisition in 2013
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Pharmasset

Acquisition in 2011
Pharmasset Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Its research centers on nucleoside analogs, which inhibit enzymes essential for viral replication. Pharmasset is advancing three product candidates: Clevudine, aimed at HBV, which is expected to enter Phase 3 clinical trials; R7128, a pro-drug for HCV currently in Phase 1 trials; and Racivir, an investigational treatment for HIV in Phase 2 trials. Through these efforts, Pharmasset seeks to provide effective treatment options for patients suffering from these viral infections.

Calistoga Pharmaceuticals

Acquisition in 2011
Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

Arresto BioSciences

Acquisition in 2010
Arresto Biosciences, Inc., a biotechnology company, develops medicines to treat cancer and fibrotic diseases by targeting molecules from the extracellular matrix. The company was incorporated in 2007 and is based in Palo Alto, California.

CGI Pharmaceuticals

Acquisition in 2010
CGI Pharmaceuticals, founded in 2000 from Yale University, focuses on the discovery and development of small molecule therapeutics for oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The company employs a unique chemical-genetics method known as ASKA (Analog Sensitive Kinase Alleles) in collaboration with various biotech and pharmaceutical partners. CGI has established a comprehensive drug discovery infrastructure that includes proprietary kinase biology, chemistry, and drug metabolism expertise. This allows the company to maintain an extensive library of over 50,000 small molecule kinase inhibitors, all designed and synthesized internally. CGI has secured eight U.S. patents for its novel collection of kinase inhibitors, which serve as the foundation for its ongoing drug discovery and development programs, including those targeting specific kinases like Btk and Syk for various therapeutic applications.

CV Therapeutics

Acquisition in 2009
CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.

Nycomed

Acquisition in 2007
Nycomed Limited, formerly known as Altana Pharma Limited. Nycomed Limited has been conducting manufacturing and tabletting operations at the Cork facility.

Raylo Chemicals

Acquisition in 2006
Raylo Chemicals Inc., a subsidiary of Germany-based specialty chemicals company.

Corus Pharma

Acquisition in 2006
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Myogen

Acquisition in 2006
Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. They believe that our advanced understanding of the biology of cardiovascular disease combined with their clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.

Corus Pharma

Venture Round in 2006
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Triangle Pharmaceuticals

Acquisition in 2003
Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.

NeXstar Pharmaceuticals

Acquisition in 1999
NeXstar Pharmaceuticals is a Pharmaceutical company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.